Is Novavax, Inc (NASDAQ:NVAX) being unfairly punished by investors?

The price of Novavax, Inc (NASDAQ:NVAX) shares last traded on Wall Street fell -5.35% to $7.07.

NVAX stock price is now -2.63% away from the 50-day moving average and -28.72% away from the 200-day moving average. The market capitalization of the company currently stands at $1.14B.

Top 5 Artificial Intelligence Stocks to Buy for 2024

By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it. According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

Sponsored

With the price target of $19, BTIG Research recently initiated with Buy rating for Novavax, Inc (NASDAQ: NVAX). On July 30, 2024, JP Morgan Downgraded its previous ‘Neutral’ rating to ‘Underweight’ on the stock keeping its target price maintained at $8, while ‘BofA Securities’ rates the stock as ‘Neutral’

In other news, YOUNG JAMES F, Former Director bought 4,000 shares of the company’s stock on Apr 14 ’25. The stock was bought for $24,406 at an average price of $6.10. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 13 ’24, Director King Rachel K. sold 4,150 shares of the business’s stock. A total of $37,435 was realized by selling the stock at an average price of $9.02. This leaves the insider owning 14,770 shares of the company worth $0.1 million. A total of 8.87% of the company’s stock is owned by insiders.

During the past 12 months, Novavax, Inc has had a low of $3.90 and a high of $23.86. The fifty day moving average price for NVAX is $7.2612 and a two-hundred day moving average price translates $9.91825 for the stock.

The latest earnings results from Novavax, Inc (NASDAQ: NVAX) was released for 2024-12-31. The company reported revenue of $88.31 million for the quarter, compared to $291.34 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -69.69 percent.

Related Posts